Latest by Barbara Jungwirth
HIV self-testing vs. professional HIV testing; the most effective influenza vaccine strategies for people with HIV; how age can affect flu vaccine efficacy; early HIV treatment and CD4:CD8 ratio normalization.
Happy days for thrice-weekly dosing; shortfalls in chronic opioid therapy monitoring; neurocognition, treatment initiation, and high CD4; the link between influenza virus shedding and CD4 count.
Housing, social support, and HIV transmissibility among people who use drugs; concerning hepatitis C incidence trends in France; frailty among people aging with HIV; untreated HIV and brain atrophy.
The rising tide of syphilis among Americans with HIV; first-line treatment with D/C/F/TAF; peculiar findings on cancer treatment rates; poor flu vaccine response among older people.
HPV vaccination and anal (vs. oral) HPV infection; single-tablet E/C/F/TDF vs. HIV-2; an HIV-positive infant’s “founder” virus; male circumcision and antiretroviral scale-up in Kenya.
Primary care providers are well positioned to screen for and prescribe PrEP, according to a recent research review -- but many PCPs feel ill equipped to prescribe what they perceive as an HIV medication.
Prevalence of non-AIDS comorbidities prior to HIV diagnosis; wealth and HIV treatment access amidst universal health care; the uncertain benefits of food supplementation; the results of universal hepatitis C treatment access.
Non-HIV components of care may be neglected during health care visits because the focus is on HIV, said Steven C. Johnson, M.D., in a recent webinar.
Substance use rates among people with HIV; the continuing risk of PML; tenofovir gel efficacy and menopause; the cumulative cost of the global fight against HIV.